7 reasons to invest in Elanix
1 – Platform technology with allogenic progenitor cells
Multiple product categories, clinical indications, and business models (B2C, B2B, licencing, private label, spin-offs)
2 – Biotech products but no Pharma/Biologics (specialty cosmetics, medical devices, e-health)
Faster to market, less investment required, no binary outcome, lower regulatory risk
3 – 100+ patients treated over 10+ years and counting at the CHUV in Lausanne
Life-saving and life-improving products, no known clinical risks or side effects
4 – Owner of vast GMP-certified progenitor cell bank
Unique raw material: billions of potent, immunologically neutral cells in stock, audited book value of € 24 million
5 – Patent granted (cell bank set-up)
Protected process in key economies: USA, Japan, Taiwan, EU, Hong Kong
6 – First Product GYNrepair already launched in Europe
Generating early revenues with 300+ million women affected by targeted symptoms, low competition intensity yet high potential
7 – First license-out agreement in Far East
Revenue potential from royalties
DOCUMENTS
Fact Sheet
Confidential DOCUMENTS
- Elanix Equity Research (Industry Note) by Goetz Partners (Jan. 2018)
- Independent Assessment of Elanix “Asklepios Advisors – Conceptual Framework” (Dec. 2017)
- Elanix Investor Presentation with audio voiceover [21:53] (Nov. 2017)